Author:
Wang Chengwei,Li Xiaoqin,Zhang Chuanmeng,Xiao Li,Xian Jianchun
Abstract
AbstractIsolated anti-HBc (IAHBc) is defined by the presence of anti-HBc in the absence of HBsAg and hepatitis B surface antibody (anti-HBs). IAHBc is of great clinical significance as a specific pattern of HBV infection, but IAHBc has not been fully clarified. This study aimed to explore the prevalence and influential factors of IAHBc from routine examination results of inpatients.A total of 61,247 individuals were included in the study, with a median age of 55 years (range: 43–68), and a male-to-female ratio of 0.90:1. The prevalence of current HBV infection (HBsAg positive) was 6.82%, while the prevalence of previous HBV infection (HBsAg negative but anti-HBc positive) was 48.63%. The prevalence of IAHBc was 12.31%. Among them, the rates for males were 7.10%, 52.16%, and 13.70%, respectively, which were significantly higher than the rates for females at 6.56%, 45.45%, and 11.06% (P < 0.05). The prevalence rates mentioned above were significantly reduced after vaccination (P < 0.05). The prevalence of IAHBc increases with age, rising from 0.23% in the age group of 15–29 years to 13.57% in individuals aged 80 and above. After the age of 50, the prevalence of IAHBc closely parallels the previous infection rate but shows no significant association with the current infection rate (P > 0.05). Among IAHBc individuals, approximately 33.83% tested positive for anti-HBe, and their anti-HBc absorbance values were significantly higher compared to anti-HBe negative individuals (7.08 and 5.31, P < 0.01). The prevalence of anti-HBe positivity among IAHBc individuals does not vary with changes in the previous infection rate and age (P > 0.05).
Funder
Taizhou People's Hospital Scientific Research Fund Project
Taizhou Science and Technology Support Project (Social Development)
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016–2021: Actions for impact[EB/ OL]. https://apps.who.int/iris/bitstream/handle/10665/342808/9789240030985-eng.pdf.
2. Kramvis, A. et al. A roadmap for serum biomarkers for hepatitis B virus: Current status and future outlook. Nat. Rev. Gastroenterol. Hepatol. 20, 1–19. https://doi.org/10.1038/s41575-022-00649-z (2022).
3. Guiying, C. et al. Countdown on hepatitis B elimination by 2030: The global burden of liver disease related to hepatitis B and association with socioeconomic status. Hepatol. Int. 16, 1282–1296. https://doi.org/10.1007/s12072-022-10410-y (2022).
4. Bréchot, C. et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely “occult”?. Hepatology 34(1), 194–203. https://doi.org/10.1053/jhep.2001.25172 (2001).
5. Yang, H. C. et al. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection. J. Hepatol. 69(2), 286–292. https://doi.org/10.1016/j.jhep.2018.02.033 (2018).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献